Healthcare shares are lower in pre-market, while PDL BioPharma, Inc. ( PDLI ) said it agreed to provide $60 million in debt financing to LENSAR, Inc., a leader in next-generation femtosecond laser technology for refractive cataract surgery.
The financing is part of a package that will see a total of $87 million go to Lensar.
In exchange, PDL received a security interest in all of Lensar's assets and will receive interest on the principal amount outstanding.
PDLI is flat pre-bell in a 52-week range of $6.50 - $8.48.
And, Response Genetics ( RGDX ), which makes molecular diagnostic tests that help determine a patient's response to cancer therapy, said it agreed to join Fortified Provider Network's network of preferred providers. RGDX is flat at $3.32 in pre-market.
The accord gives about 4.1 million members associated with over 200 health insurers, access Response Genetics' suite of molecular predictive testing at a discounted rate. No financial terms of the accord were provided.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.